Hydroxychloroquine relative bioavailability: within subject reproducibility
Open Access
- 1 March 1996
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 41 (3) , 244-246
- https://doi.org/10.1111/j.1365-2125.1996.tb00190.x
Abstract
Six healthy volunteers received hydroxychloroquine sulphate 200 mg orally on four occasions (three tablets, one solution). Maximum hydroxychloroquine blood concentration (Cmax; range 135–422 ng ml‐1) and time to maximum (tmax; range 1.5–7.0 h) for the three tablet doses showed significant differences between subjects (P < 0.009; between subject coefficients of variation (CVs) 34% and 27%, respectively). There were no within subject differences in Cmax (P= 0.32; mean within subject CV 11%), Cmax corrected for weight (P= 0.28) or tmax (P= 0.35; mean within subject CV 16%). Truncated areas under the hydroxychloroquine blood concentration‐time curve of the three tablets were different between (P= 0.0001) but not within subjects (P= 0.13). Again, between subject CV (38%) was more than three times the mean within subject CV (12%). Bioavailability was not limited by tablet formulation. The significant variability in relative bioavailability between but not within individuals indicated that individualising dosing to target concentrations associated with optimal outcomes may minimise variability in response.Keywords
This publication has 7 references indexed in Scilit:
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Clinical Pharmacokinetics of Slow-Acting Antirheumatic DrugsClinical Pharmacokinetics, 1993
- The determination of the absolute bioavailability for drug substances with long elimination half-lives (with PC-programs for the method of truncated areas)Computer Methods and Programs in Biomedicine, 1992
- Bioavailability of Hydroxychloroquine Tablets Assessed with Deconvolution TechniquesJournal of Pharmaceutical Sciences, 1992
- High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at ph 11, with fluorimetric detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Bioavailability of drugs with long elimination half-livesEuropean Journal of Clinical Pharmacology, 1983
- Comparative Bioavailabilities from Truncated Blood Level CurvesJournal of Pharmaceutical Sciences, 1975